People with wild-type transthyretin amyloid cardiomyopathy (ATTR-CM) are significantly more likely to have a history of agricultural work, manual labor, and greater upper-body physical…
News
Use of the approved therapy Wainua (eplontersen) effectively slows disease progression and improves quality of life among adults with hereditary transthyretin amyloidosis with…
Amvuttra (vutrisiran) was associated with improvements in quality of life and physical function in adults with transthyretin amyloidosis with cardiomyopathy (ATTR-CM). That’s according…
HATTR-PN
NewsEarly nerve damage seen in woman with rare TTR mutation
A rare mutation in the TTR gene — mutations in which are the cause of hereditary transthyretin amyloidosis (hATTR) — resulted in early, progressive neurological…
Alnylam Pharmaceuticals is supporting two initiatives aiming to transform transthyretin amyloid cardiomyopathy (ATTR-CM) management, with a focus on earlier diagnosis and more coordinated…
A blood test commonly used to help diagnose Alzheimer’s disease may also identify people with hereditary transthyretin amyloidosis with polyneuropathy (hATTR-PN), characterized by damage…
Women with transthyretin amyloid cardiomyopathy (ATTR-CM) show differences in disease features and greater physical limitations than men, but are less likely to be given…
Six months of treatment with Amvuttra (vutrisiran) appears to maintain or slightly improve clinical status and quality of life among adults with hereditary…
Blood levels of the transthyretin (TTR) protein at the start of Vyndaqel (tafamidis) treatment and after one month may help identify which patients with wild-type…
Hereditary transthyretin amyloidosis with polyneuropathy (hATTR-PN) was a common clinical manifestation among people carrying a mutation in the TTR gene called p.Ala117Ser, according to…
Recent Posts
- Long-term therapy slows health decline for ATTR-CM patients
- Study suggests doctors test hATTR patients for nerve damage
- Imaging data show approved ATTR-CM therapy improves heart structure
- Treatment switch slows neuropathy progression in hATTR-PN study
- 1 ATTR-CM drug may best another for preserving heart health, analysis finds